非小细胞肺癌EGFR基因突变的临床意义研究

郑军; 谢贵元; 李姣; 罗佳娣; 文秋元; 范松青

doi:10.3969/j.issn.1000-8179.20140495

非小细胞肺癌EGFR基因突变的临床意义研究

doi: 10.3969/j.issn.1000-8179.20140495

郑军^{①, ②,},
谢贵元^③,
李姣^①,
罗佳娣^①,
文秋元^①,
范松青^①, ,

①.
中南大学湘雅二医院病理科（长沙市 410011）
②.
长治医学院生物化学教研室
③.
肿瘤科

基金项目:

国家自然科学基金 81272566

详细信息

作者简介:
郑军硕士，讲师。研究方向为eIF4E在头颈部肿瘤和肺癌中的机制研究。E-mail：zhengjun8983@163.com

通讯作者:
范松青 E-mail:songqingfan2000@yahoo.com

计量
- 文章访问数: 25
- HTML全文浏览量: 4
- PDF下载量: 4
- 被引次数: 0
出版历程
- 收稿日期: 2014-03-26
- 修回日期: 2014-05-30
- 刊出日期: 2020-12-31

Clinical significance of EGFR mutations in non-small cell lung cancer

ZHENG Jun^{①, ②
,},
XIE Guiyuan^③,
LI Jiao^①,
LUO Jiadi^①,
WEN Qiuyuan^①,
FAN Songqing^{①
, ,}

①.
Department of Pathology, The Second Xiangya Hospital of Central South University, Changsha 410011, China
②.
Department ofBiochemistry, Changzhi Medical College, Changzhi, Shanxi, 046000, China
③.
Department of Oncology, the Second XiangYa Hospital of Central South University, Changsha, 410011, China

Funds:

the National Natural Science Foundation of China 81272566

More Information

Corresponding author: Songqing FAN; E-mail:songqingfan2000@yahoo.com

摘要

摘要: 目的探讨非小细胞肺癌EGFR基因外显子突变与其临床病理特征的关系。方法利用ADx-ARMS^®EGFR基因突变检测试剂盒，检测214例未接受过Gefitinib治疗的非小细胞肺癌患者组织中EGFR基因外显子18、19、20和21突变。结果非小细胞肺癌组织中EGFR基因总突变率为45.8%（98/214），外显子18、19、20和21的突变率分别为0.93%（2/214）、22.0%（47/214）、2.3%（5/ 214）和20.6%（44/214）。另有2例19和21外显子双重突变。EGFR基因在肺腺癌组织中的总突变率为50.3%（93/185）明显高于肺鳞状细胞癌17.2%（5/29）（P=0.001）。EGFR基因在女性患者中的突变率57.0%（57/100）高于男性36.0%（41/114）（P=0.002），EGFR基因在NSCLC淋巴结转移患者中的突变率（66.7%）显著高于无淋巴结转移患者（39.5%）（P < 0.05），但EGFR基因突变率与肺癌患者的年龄、肿瘤分级和临床分期均无显著性差异（P>0.05）。结论中国肺癌尤其是肺腺癌患者存在EGFR基因的较高突变率，EGFR外显子19、21突变结合肺癌的临床病理特征有望成为评估TKI治疗非小细胞肺癌疗效的分子标志。
- 非小细胞肺癌 /
- 表皮生长因子 /
- 突变
Abstract: Objective To investigate the mutations of the epidermal growth factor receptor (EGFR) gene and its clinical significance in non-small cell lung cancer (NSCLC). Methods The EGFR gene mutations of exons 18 to 21 in NSCLC were detected by using the ADx-ARMS^® detection kit method. Results The total mutation percentage in exons 18 to 21 of the EGFR gene was 45.8% (98/ 214) in NSCLC. These mutations predominantly occur in exons 19 and 21. EGFR gene mutation percentages were found in exons 18 (0.93%, 2/214), 19 (22.0%, 47/214), 20 (2.3%, 5/214), and exon 21 (20.6%, 44/214) in the NSCLC. Two NSCLC cases were identified to have double EGFR gene mutations of exons 19 and 21. EGFR gene mutations were more frequently observed with adenocarcinoma histology (50.3%, 93/185) than with squamous cell carcinoma (17.2%, 5/29) (P=0.001). EGFR gene mutations occur more frequently in NSCLC cases in women than in men (P=0.002). EGFR gene mutations were significantly higher in NSCLC with lymphatic metastasis (66.7%) than in NSCLC without lymphatic metastasis (39.5%) (P < 0.05). However, no evident association was found between EGFR gene mutations and age, as well as tumor grade and clinical stage of NSCLC (P>0.05). Conclusion NSCLC, especially lung adenocarcinomas, has exhibits frequent EGFR gene mutations in China. EGFR gene mutations in exons 19 and 21, combined with the clinical pathological features of lung cancer, can serve as the molecular marker to evaluate the efficacy of EGFR TKI for NSCLC patients.
- NSCLC /
- EGFR /
- mutation

HTML全文

表 1 214例非小细胞肺癌患者EGFR基因突变分析

Table 1. Analysis of EGFR gene mutations in 214 cases of NSCLC

表 2 EGFR基因突变与非小细胞肺癌患者临床病理特征的关系

Table 2. Association between the EGFR gene mutations and clinicopathological features of NSCLC

AD：Adenocarcinoma，SCC：Squamous cell carcinoma；For the chi square test，*P=0.002 and **P=0.001 are considered statistically significant

表 3 EGFR基因突变与68例手术切除非小细胞肺癌患者临床病理特征的关系

Table 3. Association between the EGFR gene mutations and clinicopathological features in 68 cases of surgically resected NSCLC

For the Chi square test，*P < 0.05 is considered statistically significant

参考文献(16)

[1]	Jemal A, Siegel R, Ward E, et al. Cancer statistics[J]. CA Cancer J Clin, 2009, 59(4):225-249. doi: 10.3322/caac.20006
[2]	Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008[J]. Int J Cancer, 2010, 127(12):2893-2917. doi: 10.1002/ijc.25516
[3]	Song SY, DAS AK, Minna JD, et al. Comparison between concur rent and sequential chemoradiation for non-small cell lung cancer in vitro[J]. Oncol Lett, 2014, 7(2):307-310. doi: 10.3892/ol.2013.1707
[4]	Yoshida T, Ishii G, Goto K, et al. Solid predominant histology pre dicts EGFR tyrosine kinase inhibitor response in patients with EG FR mutation-positive lung adenocarcinoma[J]. Cancer Res Clin Oncol, 2013, 139(10):1691-1700. doi: 10.1007/s00432-013-1495-0
[5]	Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. N Engl J Med, 2004, 350 (21):2129-2139. doi: 10.1056/NEJMoa040938
[6]	Siegelin MD, Borczuk AC. Epidermal growth factor receptor muta tions in lung adenocarcinoma[J]. Lab Invest, 2014, 94(2):129-137. doi: 10.1038/labinvest.2013.147
[7]	Wu JY, Shih JY, Chen KY, et al. Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epi dermal growth factor receptor(EGFR) mutations[J]. Medicine, 2011, 90(3):159-167.
[8]	Sahoo R, Harini VV, Babu VC, et al. Screening for EGFR muta tions in lung cancer, a report from India[J]. Lung Cancer, 2011, 73 (3):316-319. https://www.sciencedirect.com/science/article/pii/S0169500211000304
[9]	Bae NC, Chae MH, Lee MH, et al. EGFR, ERBB2, and KRAS mu tations in Korean non-small cell lung cancer patients[J]. Cancer Genet Cytogenet, 2007, 173(2):107-113. doi: 10.1016/j.cancergencyto.2006.10.007
[10]	Huang YS, Yang JJ, Zhang XC, et al. Impact of smoking status and pathologic type on epidermal growth factor receptor mutations in lung cancer[J]. Chin Med J, 2011, 124(16):2457-2460. http://cn.bing.com/academic/profile?id=f85f1f3f9d622e81906bb1277a61eb50&encoded=0&v=paper_preview&mkt=zh-cn
[11]	Kim HR, Lee JC, Kim YC, et al. Clinical characteristics of non-small cell lung cancer patients who experienced acquiredresistance during gefitinib treatment[J]. Lung Cancer, 2014, 83(2):252-258. https://www.ncbi.nlm.nih.gov/pubmed/24309368
[12]	Westwood M, Joore M, Whiting P, et al. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis[J]. Health Tech nol Assess, 2014, 18(32):1-166. https://pubmed.ncbi.nlm.nih.gov/24827857/
[13]	Kuiper JL, Heideman DA, Thunnissen E, et al. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-pa tients[J]. Lung Cancer, 2014, 85(1):19-24. http://cn.bing.com/academic/profile?id=c38392f64582a12322571ae3fb3a4405&encoded=0&v=paper_preview&mkt=zh-cn
[14]	Shiozawa T, Ishii G, Goto K, et al. Clinicopathological characteris tics of EGFR mutated adenosquamous carcinoma of the lung[J]. Pathol Int, 2013, 63(2):77-84. http://cn.bing.com/academic/profile?id=004cce5d557e0cb8a9cecbf2e725f660&encoded=0&v=paper_preview&mkt=zh-cn
[15]	Song J, Zhong R, Huang H, et al. Combined Treatment with Epime dium koreanum Nakai Extract and Gefitinib Overcomes Drug Re sistance Caused by T790M Mutation in Non-Small Cell Lung Can cer Cells[J]. Nutr Cancer, 2014, 66(4):682-689. http://cn.bing.com/academic/profile?id=6a761bad07d2878acd8f4d2b25f61341&encoded=0&v=paper_preview&mkt=zh-cn
[16]	de Biase D, Visani M, Malapelle U, et al. Next-generation sequenc ing of lung cancer EGFR exons 18-21 allows effective molecular di agnosis of small routine samples (cytology and biopsy) [J]. PLoS One, 2013, 8(12):e83607. doi: 10.1371/journal.pone.0083607